DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the MEDICO REMEDIES LIMITED (MEDICO) share price today?

MEDICO REMEDIES LIMITED (MEDICO) is trading at ₹38.81 on the NSE, down 0.15% on the day. Source: DocStoX.

What is the PE ratio of MEDICO REMEDIES LIMITED?

MEDICO REMEDIES LIMITED has a price-to-earnings (PE) ratio of 31.8 in the Healthcare sector.

What is the market capitalisation of MEDICO REMEDIES LIMITED?

MEDICO REMEDIES LIMITED has a market capitalisation of approximately ₹319 crore.

MEDICO REMEDIES LIMITED

MEDICO·NSE·Healthcare

₹38.81▼ -0.06 (-0.15%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹38.31

₹39.48

52W₹30

₹5732%

Open

₹39.44

High

₹39.48

Low

₹38.31

Prev Close

₹38.87

Volume

83.3K

VWAP

₹38.93

Snapshot

Key fundamentals

Market Cap

₹319 Cr

P/E Ratio

31.81Fair

P/B Ratio

4.29

EPS

₹1.22

Book Value

₹9.10

ROE

16.16%Strong

ROCE

21.00%Efficient

Dividend Yield

0.00%

Debt / Equity

0.25Low

Face Value

₹2.00

52W High

₹56.88

52W Low

₹30.22

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹12

▼ 68.9%downside

Trading at ₹39 — 69% above our estimate

BearFair valueBull

₹10₹12₹16

/100

Business quality — Watch the fundamentals

Growth 0Profitability 41Efficiency 49Valuation 66

Plain English

Our view

Revenue under pressure recently
Low debt relative to equity
Revenue has been shrinking

Strengths

Low debt relative to equity
Capital is working hard (ROCE 21%)
Promoters hold a controlling stake

Risks

Revenue has been shrinking

How we got there

Fair value methods

Residual income

16% ROE fading to 12% over ~10 yrs, on ₹9 book

₹11

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹16

Analyst target

No analyst coverage

—

Blended fair value₹12

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Capital is working hard (ROCE 21%)
Promoters hold a controlling stake

Bear case

Revenue has been shrinking

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

31.8Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

16.2%Strong

Above 15% is considered healthy for Indian equities

ROCE

21.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.25Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹319 Cr

P/B

4.29

EPS

₹1.22

Div Yield

—

What changed

Recent changes

Foreign investors-0.5% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 31.8×

Growth

Steady

+14% rev CAGR

Profitability

Healthy

16.2% ROE

Financial health

Rock solid

D/E 0.25

Momentum

N/A

No technicals

Today

Trading activity

Delivery %78.9%

Turnover₹32.42L Cr

Trades346

VWAP₹38.93

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+13.8%

+11.1%

10Y

+11.9%

Profit

+23.3%

+34.3%

10Y

+29.4%

EPS

—

10Y

—

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 38.3% CAGR over last 5 years

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 11.0% over past five years.
Earnings include an other income of Rs.5.93 Cr.
Promoter holding has decreased over last 3 years: -12.0%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.46 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

61%

Promoter

Promoters

61.4%0.00

Public

38.6%+0.47

FII / FPI

0.0%-0.46

DII

0.0%0.00

Total shareholders

16,189-373 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter61.38%

FII0.03%

Public38.60%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]